JP2014533299A5 - - Google Patents

Download PDF

Info

Publication number
JP2014533299A5
JP2014533299A5 JP2014542393A JP2014542393A JP2014533299A5 JP 2014533299 A5 JP2014533299 A5 JP 2014533299A5 JP 2014542393 A JP2014542393 A JP 2014542393A JP 2014542393 A JP2014542393 A JP 2014542393A JP 2014533299 A5 JP2014533299 A5 JP 2014533299A5
Authority
JP
Japan
Prior art keywords
optionally substituted
cancer
pharmaceutical composition
alkyl
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014542393A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014533299A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/064967 external-priority patent/WO2013074594A1/en
Publication of JP2014533299A publication Critical patent/JP2014533299A/ja
Publication of JP2014533299A5 publication Critical patent/JP2014533299A5/ja
Pending legal-status Critical Current

Links

JP2014542393A 2011-11-14 2012-11-14 Ｂｒａｆ阻害剤とｈｓｐ９０阻害剤の組合せ療法 Pending JP2014533299A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161559486P 2011-11-14 2011-11-14
US61/559,486 2011-11-14
PCT/US2012/064967 WO2013074594A1 (en) 2011-11-14 2012-11-14 Combination therapy of hsp90 inhibitors with braf inhibitors

Publications (2)

Publication Number Publication Date
JP2014533299A JP2014533299A (ja) 2014-12-11
JP2014533299A5 true JP2014533299A5 (OSRAM) 2016-01-07

Family

ID=47278530

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014542393A Pending JP2014533299A (ja) 2011-11-14 2012-11-14 Ｂｒａｆ阻害剤とｈｓｐ９０阻害剤の組合せ療法

Country Status (6)

Country Link
US (1) US9402831B2 (OSRAM)
EP (1) EP2780010A1 (OSRAM)
JP (1) JP2014533299A (OSRAM)
AU (1) AU2012339679A1 (OSRAM)
CA (1) CA2854188A1 (OSRAM)
WO (1) WO2013074594A1 (OSRAM)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2035396T3 (da) 2006-05-25 2014-06-02 Synta Pharmaceuticals Corp Triazolforbindelser der modulerer hsp90-aktivitet
WO2009148599A1 (en) 2008-06-04 2009-12-10 Synta Pharmaceuticals Corp. Pyrrole compunds that modulate hsp90 activity
TW201011003A (en) 2008-08-08 2010-03-16 Synta Pharmaceuticals Corp Triazole compounds that modulate HSP90 activity
CN102844313B (zh) 2010-01-28 2016-10-05 哈佛大学校长及研究员协会 提高蛋白酶体活性的组合物和方法
EP2560640A1 (en) 2010-04-19 2013-02-27 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
US9556166B2 (en) 2011-05-12 2017-01-31 Proteostasis Therapeutics, Inc. Proteostasis regulators
AU2012332424A1 (en) 2011-11-02 2014-06-05 Synta Pharmaceuticals Corp. Combination therapy of Hsp90 inhibitors with platinum-containing agents
CA2853799A1 (en) 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
US20150352086A1 (en) * 2013-01-07 2015-12-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. Heat shock protein (hsp) inhibition and monitoring effectiveness thereof
WO2014116228A1 (en) 2013-01-25 2014-07-31 President And Fellows Of Harvard College Usp14 inhibitors for treating or preventing viral infections
WO2015073528A1 (en) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
JP6497767B2 (ja) * 2013-12-16 2019-04-10 日本化薬株式会社 癌治療におけるｈｓｐ９０阻害剤の抗腫瘍効果を予測する方法
RU2722784C2 (ru) * 2013-12-20 2020-06-03 Байомед Вэлли Дискавериз, Инк. Лечение злокачественных опухолей с применением комбинаций ингибиторов erk и raf
US10005765B2 (en) 2014-03-20 2018-06-26 Capella Therapeutics, Inc. Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer
US10202398B2 (en) 2014-03-20 2019-02-12 Capella Therapeutics, Inc. Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer
SI3179992T1 (sl) 2014-08-11 2022-09-30 Acerta Pharma B.V. Terapevtske kombinacije zaviralca BTK, zaviralca PD-1 in/ali zaviralca PD-L1
TW201618773A (zh) 2014-08-11 2016-06-01 艾森塔製藥公司 Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑、及／或ｃｄｋ４／６抑制劑的治療組合物
TW201618772A (zh) 2014-08-11 2016-06-01 艾森塔製藥公司 Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑及／或ｂｃｌ－２抑制劑之治療組合物
EP3300500B9 (en) 2015-05-20 2021-01-13 Amgen Inc. Triazole agonists of the apj receptor
US10590108B2 (en) 2015-09-23 2020-03-17 Capella Therapeutics, Inc. Benzimidazoles for use in the treatment of cancer and inflammatory diseases
WO2017192485A1 (en) 2016-05-03 2017-11-09 Amgen Inc. Heterocyclic triazole compounds as agonists of the apj receptor
EP3541802B1 (en) 2016-11-16 2025-01-01 Amgen Inc. Alkyl substituted triazole compounds as agonists of the apj receptor
WO2018097944A1 (en) 2016-11-16 2018-05-31 Amgen Inc. Triazole furan compounds as agonists of the apj receptor
WO2018093577A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Cycloalkyl substituted triazole compounds as agonists of the apj receptor
EP3541810B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole phenyl compounds as agonists of the apj receptor
US10689367B2 (en) 2016-11-16 2020-06-23 Amgen Inc. Triazole pyridyl compounds as agonists of the APJ receptor
US11046680B1 (en) 2016-11-16 2021-06-29 Amgen Inc. Heteroaryl-substituted triazoles as APJ receptor agonists
WO2018134254A1 (en) 2017-01-17 2018-07-26 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
EP3375455A1 (en) * 2017-03-15 2018-09-19 Les Hôpitaux Universitaires de Genève Agents enhancing hur/elav protein levels for use in the treatment of braf-mutated cancers
CN110545853A (zh) 2017-04-28 2019-12-06 石英治疗有限公司 Raf降解偶联化合物
US11149040B2 (en) 2017-11-03 2021-10-19 Amgen Inc. Fused triazole agonists of the APJ receptor
WO2019213006A1 (en) 2018-05-01 2019-11-07 Amgen Inc. Substituted pyrimidinones as agonists of the apj receptor
WO2025073290A1 (en) * 2023-10-06 2025-04-10 Para Therapeutics, Inc. Vps4 inhibitors and methods of use thereof

Family Cites Families (218)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1001992C2 (de) 1954-05-10 1957-07-11 Hoechst Ag Verfahren zur Herstellung von 3, 5-Di-(2'-anthrachinonyl)-4-phenyl-1, 2, 4-triazolen
US2898343A (en) 1957-11-18 1959-08-04 American Cyanamid Co Anthraquinone triazoles
GB928919A (en) 1960-08-16 1963-06-19 Bellon Labor Sa Roger Triazole derivatives and a process for their preparation
US3898272A (en) 1966-05-06 1975-08-05 Bayer Ag Thionosalicylic acid anilides
DE1805156B2 (de) 1968-10-25 1976-01-29 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von 2- acyloxythionobenzamiden
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4178253A (en) 1977-04-05 1979-12-11 Ciba-Geigy Corporation Corrosion inhibited lubricant compositions
US4269846A (en) 1979-10-29 1981-05-26 Usv Pharmaceutical Corporation Heterocyclic compounds useful as anti-allergy agents
JPS5770820A (en) 1980-10-20 1982-05-01 Haruo Ogura Immunoregulating agent
JPS5910574A (ja) 1982-07-07 1984-01-20 Fujisawa Pharmaceut Co Ltd トリアゾ−ル誘導体およびその製造法
FR2546887B1 (fr) 1983-05-30 1985-08-30 Paris 7 Universite Procede de preparation de dihydro-2,4 triazol-1,2,4 thiones-3 disubstituees en positions 4 et 5 et nouveaux composes pouvant etre prepares par ce procede
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4740568A (en) 1985-04-09 1988-04-26 Minnesota Mining And Manufacturing Company Triazolinethione-containing polymer
US4624995A (en) 1985-04-09 1986-11-25 Minnesota Mining And Manufacturing Company Triazolinethione-containing polymer
US5436252A (en) 1986-12-19 1995-07-25 Merrell Dow Pharmaceuticals Inc. 5-aryl-3H-1,2,4-triazol-3-ones and their use in the treatment of neurodegenerative disorders
US5006650A (en) 1987-02-11 1991-04-09 The Upjohn Company Novel N-1 substituted beta-lactams as antibiotics
DE3729070A1 (de) 1987-09-01 1989-03-09 Bayer Ag Substituierte triazolinone
US5241074A (en) 1988-05-09 1993-08-31 Bayer Aktiengesellschaft Sulphonylaminocarbonyltriazolinones
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5219722A (en) 1990-09-21 1993-06-15 Konica Corporation Silver halide color photographic light-sensitive material
SK278998B6 (sk) 1991-02-01 1998-05-06 Merck Sharp & Dohme Limited Deriváty imidazolu, triazolu a tetrazolu, spôsob i
US5356897A (en) 1991-09-09 1994-10-18 Fujisawa Pharmaceutical Co., Ltd. 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5510362A (en) 1992-03-13 1996-04-23 Merck, Sharp And Dohme Limited Imidazole, triazole and tetrazole derivatives
TW218017B (OSRAM) 1992-04-28 1993-12-21 Takeda Pharm Industry Co Ltd
DE4222771A1 (de) 1992-07-10 1994-01-13 Bayer Ag Heterocyclyltriazolinone
DE4234801A1 (de) 1992-10-15 1994-04-21 Bayer Ag Sulfonylaminocarbonyltriazolinone
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
DE4303376A1 (de) 1993-02-05 1994-08-11 Bayer Ag Substituierte Triazolinone
DE4303676A1 (de) 1993-02-09 1994-08-11 Bayer Ag 1-Aryltriazolin(thi)one
US5529925A (en) 1993-12-03 1996-06-25 St. Jude Children's Research Hospital Nucleic acid sequences and fusion proteins present in human t(2;5) lymphoma
DE4411913A1 (de) 1994-04-07 1995-10-12 Bayer Ag Substituierte Sulfonylaminocarbonyltriazolinone
US5538988A (en) 1994-04-26 1996-07-23 Martinez; Gregory R. Benzocycloalkylazolethione derivatives
US5489598A (en) 1994-06-08 1996-02-06 Warner-Lambert Company Cytoprotection utilizing aryltriazol-3-thiones
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
JP3372365B2 (ja) 1994-08-19 2003-02-04 富士写真フイルム株式会社 ハロゲン化銀写真感光材料およびそれを用いた画像形成方法
US5525625A (en) 1995-01-24 1996-06-11 Warner-Lambert Company 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders
DE19502579A1 (de) 1995-01-27 1996-08-01 Bayer Ag Sulfonylamino(thio)carbonyl-triazolin(thi)one
US6080772A (en) 1995-06-07 2000-06-27 Sugen, Inc. Thiazole compounds and methods of modulating signal transduction
DE19521162A1 (de) 1995-06-09 1996-12-12 Bayer Ag N-Aryl-1,2,4-triazolin-5-one
DE19525162A1 (de) 1995-07-11 1997-01-16 Bayer Ag Sulfonylamino(thio)carbonylverbindungen
US6114334A (en) 1995-07-13 2000-09-05 Knoll Aktiengesellschaft Piperazine derivatives as therapeutic agents
DE19540737A1 (de) 1995-11-02 1997-05-07 Bayer Ag Substituierte Sulfonylamino(thio)carbonylverbindungen
DE19609059A1 (de) 1996-03-08 1997-09-11 Bayer Ag Substituierte Arylsulfonylamino(thio)carbonyl-triazolin(thi)one
ZA974703B (en) 1996-05-30 1997-12-30 Bayer Ag Substituted sulfonylamino(thio)carbonyl compounds.
TW467902B (en) 1996-07-31 2001-12-11 Bristol Myers Squibb Co Diphenyl heterocycles as potassium channel modulators
DE19632945A1 (de) 1996-08-16 1998-02-19 Bayer Ag Substituierte Sulfonylamino(thio)carbonylverbindungen
AU5178998A (en) 1996-11-12 1998-06-03 Sepracor, Inc. 2(r),4(s),(r),(s)- and 2(s),4(r),(r),(s)-hydroxyitraconazole- and hydroxysaperconazole derivatives
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US5968921A (en) 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration
JP3788676B2 (ja) 1997-11-11 2006-06-21 富士写真フイルム株式会社 有機エレクトロルミネツセンス素子材料およびそれを使用した有機エレクトロルミネツセンス素子
AR017200A1 (es) 1997-12-23 2001-08-22 Astrazeneca Ab Compuestos inhibidores de la proteina cinasa c, sales farmaceuticamente aceptables de los mismos, formulaciones farmaceuitcas que los comprenden, usode las mismas y proceso para la sintesis de dichos compuestos
AU3254099A (en) 1998-03-09 1999-09-27 Basf Aktiengesellschaft Hetaryl-substituted benzyl phenyl ethers, method for the production thereof, andtheir use for combating harmful fungi and animal pests
US6747055B1 (en) 1998-07-17 2004-06-08 The United States Of America As Represented By The Department Of Health And Human Services Water-soluble drugs and methods for their production
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
JP2000284412A (ja) 1999-03-30 2000-10-13 Fuji Photo Film Co Ltd 熱現像写真材料
US6492406B1 (en) 1999-05-21 2002-12-10 Astrazeneca Ab Pharmaceutically active compounds
SE9902387D0 (sv) 1999-06-22 1999-06-22 Astra Ab New pharmaceutically active compounds
US20040110684A1 (en) 1999-08-02 2004-06-10 Universite Catholique De Louvain Novel pharmaceutical compositions for modulating angiogenesis
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
WO2001024796A1 (en) 1999-10-01 2001-04-12 Smithkline Beecham Corporation 1,2,4-triazole derivatives, composition, process of making and methods of use
EP1265913A4 (en) 2000-03-24 2004-07-14 Univ Duke CHARACTERIZATION OF THE INTERACTION BETWEEN GRP94 AND A LIGAND, AND CLEANING, SCREENING AND THERAPEUTIC PROCEDURES RELATING TO IT
US20030216385A1 (en) 2000-05-19 2003-11-20 Takahiko Tobe Triazole derivatives
WO2002002123A1 (en) 2000-06-29 2002-01-10 Trustees Of Boston University Use of geldanamycin and related compounds for prophylaxis or treatment of fibrogenic disorders
IL153817A0 (en) 2000-07-19 2003-07-31 Warner Lambert Co Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
EP1322307B1 (en) 2000-07-28 2011-09-28 Sloan-Kettering Institute For Cancer Research Methods for treating cell proliferative disorders and viral infections
AU2002228772B2 (en) 2000-11-02 2005-12-08 Sloan Kettering Institute For Cancer Research Methods for enhancing the efficacy of cytotoxic agents through the use of HSP90 inhibitors
WO2002066447A1 (en) 2001-02-21 2002-08-29 Ono Pharmaceutical Co., Ltd. 4h-1,2,4-triazole-3(2h)-thione deratives as sphingomyelinase inhibitors
AU2002252179A1 (en) 2001-03-01 2002-09-19 Conforma Therapeutics Corp. Methods for treating genetically-defined proliferative disorders with hsp90 inhibitors
CA2440211A1 (en) 2001-03-09 2002-09-19 Pfizer Products Inc. Benzimidazole anti-inflammatory compounds
US20040235813A1 (en) 2001-05-03 2004-11-25 Erich Wanker Compounds that inhibit hsp90 and stimulate hsp70 and hsp40, useful in the prevention or treatment of diseases associated with protein aggregation and amyloid formation
AU2002310065B2 (en) 2001-05-23 2007-07-05 Sloan Kettering Institute For Cancer Research Method of treatment for cancers associated with elevated HER 2 levels
ES2289116T3 (es) 2001-05-24 2008-02-01 Eli Lilly And Company Nuevos derivados de pirrol como agentes farmaceuticos.
JP4102124B2 (ja) 2001-08-01 2008-06-18 富士フイルム株式会社 ハロゲン化銀乳剤およびハロゲン化銀写真感光材料
AU2002330998A1 (en) 2001-08-06 2003-02-24 Kosan Biosciences, Inc. Benzoquinone ansamycins
JP2005504789A (ja) 2001-09-13 2005-02-17 シンタ ファーマスーティカルズ コーポレイション 癌治療のための２−アロイルイミダゾール化合物
US7473695B2 (en) 2001-10-22 2009-01-06 Mitsubishi Tanabe Pharma Corporation 4-imidazolin-2-one compounds
AU2002361345B8 (en) 2001-11-28 2008-06-26 Ipsen Pharma S.A.S. 5-sulphanyl-4H-1,2,4-triazole derivatives and their use as medicine
CA2466762A1 (en) 2001-12-04 2003-06-12 Onyx Pharmaceuticals, Inc. Raf-mek-erk pathway inhibitors to treat cancer
CA2468202A1 (en) 2001-12-12 2003-06-19 Conforma Therapeutics Corporation Assays and implements for determining and modulating hsp90 binding activity
JP4399265B2 (ja) 2001-12-21 2010-01-13 ヴァーナリス（ケンブリッジ）リミテッド ３，４−ジアリールピラゾール、および癌の治療におけるそれらの使用
CA2478374C (en) 2002-03-13 2009-01-06 Eli M. Wallace N3 alkylated benzimidazole derivatives as mek inhibitors
GB0207362D0 (en) 2002-03-28 2002-05-08 Univ Liverpool Chemotherapy
GB0208516D0 (en) 2002-04-15 2002-05-22 Univ Liverpool Chemotherapy
JP2006508974A (ja) 2002-11-15 2006-03-16 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 癌を治療するためのｍｅｋ阻害剤およびカペシタビン（ｃａｐｅｃｉｔａｂｉｎｅ）を含む併用化学療法
GB0228417D0 (en) 2002-12-05 2003-01-08 Cancer Rec Tech Ltd Pyrazole compounds
GB0229618D0 (en) 2002-12-19 2003-01-22 Cancer Rec Tech Ltd Pyrazole compounds
EA009919B1 (ru) 2003-02-11 2008-04-28 Вернэлис (Кембридж) Лимитед Соединения изоксазола
EP1457499A1 (en) 2003-03-12 2004-09-15 Tufts University School Of Medicine Inhibitors of extracellular Hsp90
JP2006514994A (ja) 2003-03-13 2006-05-18 コンフォーマ・セラピューティクス・コーポレイション 長鎖および中鎖トリグリセリドを有する医薬製剤
JP2006522744A (ja) 2003-04-11 2006-10-05 ノボ　ノルディスク　アクティーゼルスカブ グルココルチコイド受容体アゴニスト療法に伴う副作用を最小化するための、１１β−ヒドロキシステロイドデヒドロゲナーゼ１型阻害剤およびグルココルチコイド受容体アゴニストを使用する併用療法
JP2006522750A (ja) 2003-04-11 2006-10-05 ノボ　ノルディスク　アクティーゼルスカブ 代謝性症候群ならびに関連の疾患および障害を治療するために、１１β−ヒドロキシステロイドデヒドロゲナーゼ１型阻害剤および抗高血圧剤を使用する併用療法
EP1615637A1 (en) 2003-04-11 2006-01-18 Novo Nordisk A/S Pharmaceutical use of substituted 1,2,4-triazoles
US7378233B2 (en) 2003-04-12 2008-05-27 The Johns Hopkins University BRAF mutation T1796A in thyroid cancers
DE10318020A1 (de) 2003-04-19 2004-11-11 Repower Systems Ag Gitterturm für eine Windkraftanlage
SE0301232D0 (sv) 2003-04-25 2003-04-25 Astrazeneca Ab Novel use
GB0309637D0 (en) 2003-04-28 2003-06-04 Cancer Rec Tech Ltd Pyrazole compounds
US20050020557A1 (en) 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors
US7691838B2 (en) 2003-05-30 2010-04-06 Kosan Biosciences Incorporated Method for treating diseases using HSP90-inhibiting agents in combination with antimitotics
US20050020534A1 (en) 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with antimetabolites
US20050054625A1 (en) 2003-05-30 2005-03-10 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with nuclear export inhibitors
US20050026893A1 (en) 2003-05-30 2005-02-03 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with immunosuppressants
US20050020556A1 (en) 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with platinum coordination complexes
US20050054589A1 (en) 2003-05-30 2005-03-10 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with antibiotics
US20050019918A1 (en) 2003-06-03 2005-01-27 Hidetoshi Sumimoto Treatment of cancer by inhibiting BRAF expression
US7329762B2 (en) 2003-06-12 2008-02-12 Merck & Co., Inc. Prodrugs of mitotic kinesin inhibitors
GB0315111D0 (en) 2003-06-27 2003-07-30 Cancer Rec Tech Ltd Substituted 5-membered ring compounds and their use
WO2005016920A1 (en) 2003-08-15 2005-02-24 Vertex Pharmaceuticals Incorporated Pyrrole compositions useful as inhibitors of c-met
JP2005084612A (ja) 2003-09-11 2005-03-31 Fuji Photo Film Co Ltd ハロゲン化銀乳剤、ハロゲン化銀感光材料、および熱現像感光材料
MXPA06003163A (es) 2003-09-23 2006-06-05 Novartis Ag Combinacion de un inhibidor de receptor de vegf con un agente quimioterapeutico.
JP2007506763A (ja) 2003-09-24 2007-03-22 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼのインヒビターとして有用なイミダゾール組成物
US20050085531A1 (en) 2003-10-03 2005-04-21 Hodge Carl N. Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
CA2542682A1 (en) 2003-10-18 2005-05-06 Bayer Healthcare Ag 5-substituted 2-(phenylmethyl) thio-4-phenyl-4h-1,2,4-triazole derivatives and related compounds as gaba-agonists for the treatment of urinary incontinence and related diseases
WO2005044194A2 (en) 2003-10-28 2005-05-19 Pharmacia Corporation TREATMENT OR PREVENTION OF NEOPLASIA BY USE OF AN Hsp90 INHIBITOR
BRPI0415896A (pt) 2003-10-28 2007-01-09 Pharmacia Corp combinações compreendendo um inibidor de hsp90 e um inibidor de fosfodiesterase para tratamento ou prevenção de neoplasia
US6855705B1 (en) 2003-11-12 2005-02-15 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
EP1723123A4 (en) 2004-03-08 2009-12-02 Wyeth Corp ION CHANNEL MODULATORS
AU2005230867A1 (en) 2004-03-26 2005-10-20 Amphora Discovery Corporation Certain triazole-based compounds, compositions, and uses thereof
WO2005105077A1 (en) 2004-04-28 2005-11-10 Massachusetts Eye & Ear Infirmary Inflammatory eye disease
EP2592155B2 (en) 2004-06-04 2019-09-11 Genentech, Inc. EGFR mutations
GB0416168D0 (en) 2004-07-20 2004-08-18 Vernalis Cambridge Ltd Pyrmidothiophene compounds
DE102004039280A1 (de) 2004-08-13 2006-02-23 Merck Patent Gmbh 1,5-Diphenyl-pyrazole
US20060078494A1 (en) 2004-09-24 2006-04-13 Sapphire Therapeutics, Inc. Use of inhibitors of 24-hydroxylase in the treatment of cancer
DE102004049078A1 (de) 2004-10-08 2006-04-13 Merck Patent Gmbh Phenylpyrazole
EP1817028A2 (en) 2004-10-25 2007-08-15 University of Medicine and Dentistry of New Jersey Anti-mitotic anti-proliferative compounds
JP2008518964A (ja) 2004-11-01 2008-06-05 ユニバーシティ オブ サザン カリフォルニア 癌と、血管新生機能に関連する疾患との治療用新規化合物
EP1817295B1 (en) 2004-11-18 2012-11-07 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
WO2006061712A2 (en) 2004-12-10 2006-06-15 Pfizer Inc. Use of mek inhibitors in treating abnormal cell growth
DE102005007304A1 (de) 2005-02-17 2006-08-24 Merck Patent Gmbh Triazolderivate
TWI382015B (zh) 2005-02-25 2013-01-11 Serenex Inc 苯、吡啶及噠嗪衍生物
CA2598899A1 (en) 2005-03-09 2006-09-14 Nippon Kayaku Kabushiki Kaisha Novel hsp90 inhibitor
US8399464B2 (en) 2005-03-09 2013-03-19 Nippon Kayaku Kabushiki Kaisha HSP90 inhibitor
JP2008137894A (ja) 2005-03-22 2008-06-19 Nippon Kayaku Co Ltd 新規なアセチレン誘導体
EP1871750A1 (en) 2005-07-06 2008-01-02 Sicor, Inc. Improved process for the preparation of letrozole
AU2006272652B2 (en) 2005-07-25 2011-06-16 Synta Pharmaceuticals Corp. 1,2,3-triazoles inhibitors of tubulin polymerization for the treatment of proliferative disorders
US7473784B2 (en) 2005-08-01 2009-01-06 Bristol-Myers Squibb Company Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
WO2007021966A1 (en) 2005-08-12 2007-02-22 Synta Pharmaceuticals Corp. Pyrazole compounds that modulate hsp90 activity
WO2007021877A1 (en) 2005-08-18 2007-02-22 Synta Pharmaceuticals Corp. Imidazole compounds that modulate hsp90 activity
CA2618628C (en) 2005-08-18 2014-11-18 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
WO2007111904A2 (en) 2006-03-22 2007-10-04 Vertex Pharmaceuticals Incorporated C-met protein kinase inhibitors for the treatment of proliferative disorders
ES2561406T3 (es) 2006-04-14 2016-02-26 Cell Signaling Technology, Inc. Defectos de genes y quinasa ALK mutante en tumores sólidos humanos
EP2025347A4 (en) 2006-05-15 2010-08-11 Takeda Pharmaceutical PROPHYLACTIC AND THERAPEUTIC AGENTS AGAINST CANCER
DE102006023337A1 (de) 2006-05-18 2007-11-22 Merck Patent Gmbh Triazolderivate II
CA2653222A1 (en) 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
DK2035396T3 (da) 2006-05-25 2014-06-02 Synta Pharmaceuticals Corp Triazolforbindelser der modulerer hsp90-aktivitet
WO2007140002A2 (en) 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Method for treating non-hodgkin's lymphoma
WO2007139952A2 (en) 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Method for the preparation of triazole compounds with hsp90 modulating activity
US8034834B2 (en) 2006-05-25 2011-10-11 Synta Pharmaceuticals Corp. Method for treating proliferative disorders with HSP90 inhibitors
WO2007139960A2 (en) 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Compounds that modulate hsp90 activity and methods for identifying same
AU2012200157B2 (en) 2006-05-25 2014-08-21 Synta Pharmaceuticals Corp. Method for treating proliferative disorders associated with protooncogene products
EP2038262B1 (en) 2006-05-25 2014-11-12 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
CA2659425C (en) 2006-08-17 2017-06-20 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
US20110046125A1 (en) 2006-10-19 2011-02-24 Synta Pharmaceuticals Corp. Method for treating infections
WO2008057246A2 (en) 2006-10-26 2008-05-15 Synta Pharmaceuticals Corp. Method for treating inflammatory disorders
DE102007002715A1 (de) 2007-01-18 2008-07-24 Merck Patent Gmbh Triazolderivat
CN101679319B (zh) 2007-02-08 2014-07-09 辛塔医药品有限公司 用于治疗增生性病症如癌症的三唑类化合物
CN101641117B (zh) 2007-03-05 2012-06-13 协和发酵麒麟株式会社 药物组合物
US8993608B2 (en) 2007-03-12 2015-03-31 Synta Pharmaceuticals Corp. Method for inhibiting topoisomerase II
WO2008118391A2 (en) 2007-03-27 2008-10-02 Synta Pharmaceuticals Corp. Triazinone and diazinone derivatives useful as hsp90 inhibitors
US20100203043A1 (en) 2007-04-13 2010-08-12 Ree Anne H Treatment and diagnosis of metastatic prostate cancer with inhibitors of epidermal growth factor receptor (egfr)
WO2008153730A2 (en) 2007-05-25 2008-12-18 Synta Pharmaceuticals Corp. Method for treating proliferative disorders associated with mutations in c-met
WO2008156573A1 (en) 2007-06-12 2008-12-24 Provid Pharmaceuticals, Inc. Kinase inhibitors, compositions thereof, and methods of use therewith
US20080318241A1 (en) 2007-06-18 2008-12-25 The Regents Of The University Of Michigan Methods and Systems for Detecting Antiangiogenesis
EP2193135A1 (en) 2007-08-13 2010-06-09 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
KR20100102609A (ko) 2007-11-12 2010-09-24 바이파 사이언스 인코포레이티드 Ｐａｒｐ 억제제를 단독으로 사용하거나 항종양제와 병용하여 유방암을 치료하는 방법
US20110053879A1 (en) 2008-02-08 2011-03-03 Poniard Pharmaceuticals, Inc. Picoplatin and amrubicin to treat lung cancer
JP2011511949A (ja) 2008-02-12 2011-04-14 ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド 肺癌におけるｅｍｌ４とａｌｋの融合のためのｆｉｓｈアッセイ
US20090232906A1 (en) 2008-03-14 2009-09-17 Bionumerik Pharmaceuticals, Inc. Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions
WO2009139916A1 (en) 2008-05-16 2009-11-19 Synta Pharmaceuticals Corp. Tricyclic triazole compounds that modulate hsp90 activity
WO2009148599A1 (en) 2008-06-04 2009-12-10 Synta Pharmaceuticals Corp. Pyrrole compunds that modulate hsp90 activity
US8648071B2 (en) 2008-06-27 2014-02-11 Synta Pharmaceuticals Corp. Hydrazonamide compounds that modulate Hsp90 activity
TW201011003A (en) 2008-08-08 2010-03-16 Synta Pharmaceuticals Corp Triazole compounds that modulate HSP90 activity
ES2415234T3 (es) 2008-08-08 2013-07-24 Synta Pharmaceuticals Corp. Compuestos de triazol que modulan la actividad Hsp90
US20110319415A1 (en) 2008-08-18 2011-12-29 Universit+e,uml a+ee t zu K+e,uml o+ee ln Susceptibility to HSP90-Inhibitors
JP2012510442A (ja) 2008-11-28 2012-05-10 ノバルティス アーゲー Ｈｓｐ９０阻害剤の組合せ
US20100209929A1 (en) 2009-01-14 2010-08-19 Nodality, Inc., A Delaware Corporation Multiple mechanisms for modulation of jak/stat activity
WO2010138377A1 (en) 2009-05-28 2010-12-02 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
RS53716B1 (sr) * 2009-10-19 2015-04-30 Synta Pharmaceuticals Corp. Kombinovana terapija kancera sa hsp90 inhibitornim jedinjenjima
EP2499486A4 (en) 2009-11-13 2013-11-27 Infinity Pharmaceuticals Inc COMPOSITIONS, KITS, AND METHODS FOR IDENTIFICATION, EVALUATION, PREVENTION, AND THERAPY OF CANCER
EP2333103A1 (en) 2009-12-11 2011-06-15 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Differential diagnosis and therapy for kinase inhibitors
EP2560641A2 (en) * 2010-04-19 2013-02-27 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a vegf inhibitor
EP2560640A1 (en) 2010-04-19 2013-02-27 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
US20130172333A1 (en) 2010-05-20 2013-07-04 Synta Pharmaceuticals Corp. Formulation and dosing of hsp90 inhibitory compounds
AU2011255438A1 (en) 2010-05-20 2013-01-10 Synta Pharmaceuticals Corp. Method of treating lung adenocarcinoma with Hsp90 inhibitory compounds
EP2575810A1 (en) 2010-05-24 2013-04-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compound and a topoisomerase ii inhibitor
US20130225870A1 (en) 2010-08-25 2013-08-29 Synta Pharmaceuticals Corp. Method of synthesizing substituted 2-alkyl phenols
AU2011302344B2 (en) 2010-09-13 2015-01-15 Synta Pharmaceuticals Corp. HSP90 inhibitors for treating non-small cell lung cancers in wild-type EGFR and/or KRAS patients
JP2014503500A (ja) 2010-11-18 2014-02-13 シンタ ファーマスーティカルズ コーポレーション 低酸素状態に基づく酸素感受性薬剤による治療に適した被験体の事前選択
WO2012068483A1 (en) 2010-11-18 2012-05-24 Synta Pharmaceuticals Corp. Preselection of subjects for therapeutic treatment based on hypoxic status
EP2648708A2 (en) 2010-12-08 2013-10-16 Synta Pharmaceuticals Corp. Combination for breast cancer therapy with hsp90 inhibitory compounds
WO2012096919A1 (en) 2011-01-11 2012-07-19 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with proteasome inhibitors
EP2678013A1 (en) 2011-02-23 2014-01-01 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with radiotherapy
CN103391779A (zh) 2011-02-24 2013-11-13 辛塔医药品有限公司 使用hsp90抑制性化合物的前列腺癌治疗
US20140045908A1 (en) 2011-02-25 2014-02-13 Synta Pharmaceuticals Corp. Hsp90 inhibitory compounds in treating jak/stat signaling-mediated cancers
MY181439A (en) * 2011-02-28 2020-12-22 Sunshine Lake Pharma Co Ltd Substituted quinoline compounds and methods of use
WO2012155063A1 (en) 2011-05-11 2012-11-15 Synta Pharmaceuticals Corp. Treating cancer with an hsp90 inhibitory compound
US20140228418A1 (en) 2011-05-23 2014-08-14 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with mek inhibitors
EP2714038A1 (en) 2011-05-24 2014-04-09 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with mtor/pi3k inhibitors
US20140194388A1 (en) 2011-05-26 2014-07-10 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with chk inhibitors
EP2729144A2 (en) 2011-07-07 2014-05-14 Synta Pharmaceuticals Corp. Treating cancer with hsp90 inhibitory compounds
WO2013028505A1 (en) 2011-08-19 2013-02-28 Synta Pharmaceuticals Corp. Combination cancer therapy of hsp90 inhibitor with antimetabolite
US8628752B2 (en) 2011-10-28 2014-01-14 Synta Pharmaceuticals Corp. Methods of identifying HSP90 inhibitors with less ocular toxicity
AU2012332424A1 (en) 2011-11-02 2014-06-05 Synta Pharmaceuticals Corp. Combination therapy of Hsp90 inhibitors with platinum-containing agents
CA2853799A1 (en) 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
AU2013239663A1 (en) 2012-03-28 2014-10-09 Synta Pharmaceuticals Corp. Triazole derivatives as HSP90 inhibitors
US20150119395A1 (en) 2012-04-04 2015-04-30 Synta Pharmaceuticals Corp. Novel triazole compounds that modulate hsp90 activity
AU2013259267A1 (en) 2012-05-10 2014-11-06 Synta Pharmaceuticals Corp. Treating cancer with Hsp90 inhibitory compounds
US10155987B2 (en) 2012-06-12 2018-12-18 Dana-Farber Cancer Institute, Inc. Methods of predicting resistance to JAK inhibitor therapy
US20150283147A1 (en) 2012-10-19 2015-10-08 Synta Pharmaceuticals Corp. Treating polycystic kidney disease with hsp90 inhibitory compounds
WO2014189937A1 (en) 2013-05-21 2014-11-27 Synta Pharmaceuticals Corp. Specific cancer treatment regimens with ganetespib
US20160324863A1 (en) 2014-01-17 2016-11-10 Synta Pharmaceuticals Corp. Targeted cancer treatment by hsp90 inhibitors ganetespib and nvp-auy922

Similar Documents

Publication Publication Date Title
JP2014533299A5 (OSRAM)
JP2013537229A5 (OSRAM)
JP2013508378A5 (OSRAM)
JP2014507443A5 (OSRAM)
JP2011509949A5 (OSRAM)
JP2010241830A5 (OSRAM)
JP2012526148A5 (OSRAM)
JP2008535902A5 (OSRAM)
JP2016513137A5 (OSRAM)
JP2013516393A5 (OSRAM)
JP2014513704A5 (OSRAM)
JP2011511095A5 (OSRAM)
JP2011515397A5 (OSRAM)
JP2012505235A5 (OSRAM)
JP2013523756A5 (OSRAM)
JP2018524403A5 (OSRAM)
JP2017526662A5 (OSRAM)
JP2012532100A5 (OSRAM)
JP2015531747A5 (OSRAM)
JP2017528475A5 (OSRAM)
JP2013502423A5 (OSRAM)
NZ701290A (en) Pyrrolobenzodiazepines
JP2013535491A5 (OSRAM)
JP2015520753A5 (OSRAM)
JP2013510860A5 (OSRAM)